Document Type
Article
Publication Date
2-9-2022
Publication Title
Nat Commun
Keywords
JGM
JAX Source
Nat Commun 2022 Feb 9; 13(1):767
Volume
13
Issue
1
First Page
767
Last Page
767
ISSN
2041-1723
PMID
35140215
DOI
https://doi.org/10.1038/s41467-022-28372-y
Abstract
A major rate-limiting step in developing more effective immunotherapies for GBM is our inadequate understanding of the cellular complexity and the molecular heterogeneity of immune infiltrates in gliomas. Here, we report an integrated analysis of 201,986 human glioma, immune, and other stromal cells at the single cell level. In doing so, we discover extensive spatial and molecular heterogeneity in immune infiltrates. We identify molecular signatures for nine distinct myeloid cell subtypes, of which five are independent prognostic indicators of glioma patient survival. Furthermore, we identify S100A4 as a regulator of immune suppressive T and myeloid cells in GBM and demonstrate that deleting S100a4 in non-cancer cells is sufficient to reprogram the immune landscape and significantly improve survival. This study provides insights into spatial, molecular, and functional heterogeneity of glioma and glioma-associated immune cells and demonstrates the utility of this dataset for discovering therapeutic targets for this poorly immunogenic cancer.
Recommended Citation
Abdelfattah N,
Kumar P,
Wang C,
Leu J,
Flynn W,
Gao R,
Baskin D,
Pichumani K,
Ijare O,
Wood S,
Powell S,
Haviland D,
Parker Kerrigan B,
Lang F,
Prabhu S,
Huntoon K,
Jiang W,
Kim B,
George J,
Yun K.
Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun 2022 Feb 9; 13(1):767
Comments
We thank Tetsuo Ashizawa, Dorothy Lewis, Brandi Mattson, and Taneli Helenius for
their editorial and Matthew G. Landry for graphic design assistance.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License.